Baxter Healthcare Corporation initiated a recall of Vasopressin in 0.9% Sodium Chloride Injection on August 6, 2026. The action is classified as a Class II recall by the FDA. The recalled product is a 20 units per 100 mL (0.2 units/mL) formulation in a 100 mL single-dose container, NDC 0338-9640-12, manufactured at Baxter's Deerfield, IL facility. The stated reason for the recall is CGMP deviations. The recall status is listed as ongoing as of the reporting date. This is a Class II classification, meaning specific criteria apply to how the FDA categorizes such actions. No additional details about the nature of the deviations or affected lot numbers were included in the event record. The recall pertains specifically to this Baxter-manufactured product and its associated NDC code. Facilities and providers using this product may reference the recall identifier D-0811-2026 for tracking purposes through FDA recall channels. For general background on vasopressin as a compound, readers can consult the compound overview page.
Vasopressin Injection Recalled by Baxter Over CGMP Deviations
See the full vasopressin overview
Source: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts